Literature DB >> 25854163

MRTF-A and STAT3 promote MDA-MB-231 cell migration via hypermethylating BRSM1.

Wen-Jing Xing1, Xing-Hua Liao, Nan Wang, Dong-Wei Zhao, Li Zheng, De-Liang Zheng, Jian Dong, Tong-Cun Zhang.   

Abstract

Breast cancer is the leading cause of cancer death in women worldwide which is closely related to metastasis. But the exact molecular mechanism of metastasis is still not fully understood. We now report that both MRTF-A and STAT3 play important roles in migration of MDA-MB-231 breast cancer cells. Moreover, MRTF-A and STAT3 synergistically increased MDA-MB-231 cell migration by promoting the expression of migration markers urokinase-type plasminogen activator (uPA) and osteopontin (OPN) and inhibiting the expression of breast cancer metastasis suppressor 1 (BRMS1). Luciferase reporter assays demonstrated that MRTF-A and STAT3 do not affect transcription of the BRMS1 promoter. Instead, we identified a newly molecular mechanism by which MRTF-A and STAT3 synergistically controlled MDA-MB-231 cell migration by recruiting DNMT1 to hypermethylate the promoter of BRMS1 and thus affect the expression of BRMS1. Interestingly, physical interaction between MRTF-A and STAT3 synergistically promotes the transactivity of DNMT1 by binding to the GAS element within the DNMT1 promoter. Our data thus provide important and novel insights into the roles of MRTF-A and STAT3 in regulating MDA-MB-231 cell migration.
© 2015 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  BRSM1; DNMT1; MRTF-A; STAT3; breast cancer cell migration

Mesh:

Substances:

Year:  2015        PMID: 25854163     DOI: 10.1002/iub.1362

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  8 in total

Review 1.  SRF'ing and SAP'ing - the role of MRTF proteins in cell migration.

Authors:  David Gau; Partha Roy
Journal:  J Cell Sci       Date:  2018-10-11       Impact factor: 5.285

Review 2.  BRMS1: a multifunctional signaling molecule in metastasis.

Authors:  Rosalyn C Zimmermann; Danny R Welch
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

3.  MiR-147 inhibits cyclic mechanical stretch-induced apoptosis in L6 myoblasts via ameliorating endoplasmic reticulum stress by targeting BRMS1.

Authors:  Yanxiao Du; Feng Yang; Di Lv; Qiang Zhang; Xiao Yuan
Journal:  Cell Stress Chaperones       Date:  2019-10-18       Impact factor: 3.667

4.  miR‑215 promotes epithelial to mesenchymal transition and proliferation by regulating LEFTY2 in endometrial cancer.

Authors:  Xiaoxu Gao; Yan Cai; Ruifang An
Journal:  Int J Mol Med       Date:  2018-05-22       Impact factor: 4.101

5.  MKL-1 is a coactivator for STAT5b, the regulator of Treg cell development and function.

Authors:  Yuan Xiang; Jun Wang; Jia Peng Li; Wei Guo; Feng Huang; Hui Min Zhang; Han Han Li; Zhou Tong Dai; Zi Jian Zhang; Hui Li; Le Yuan Bao; Chao Jiang Gu; Kun Chen; Tong Cun Zhang; Xing Hua Liao
Journal:  Cell Commun Signal       Date:  2020-07-09       Impact factor: 5.712

6.  Novel interactions between ERα-36 and STAT3 mediate breast cancer cell migration.

Authors:  Yuan Xiang; Jia Peng Li; Wei Guo; Dan-Qun Wang; Ao Yao; Hui-Min Zhang; Feng Huang; Han-Han Li; Zhou-Tong Dai; Zi-Jiang Zhang; Hui Li; Yao Tan; Kun Chen; Le-Yuan Bao; Xing-Hua Liao
Journal:  Cell Commun Signal       Date:  2019-08-13       Impact factor: 5.712

Review 7.  Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery.

Authors:  Sepideh Mirzaei; Ali Zarrabi; Farid Hashemi; Amirhossein Zabolian; Hossein Saleki; Negar Azami; Soodeh Hamzehlou; Mahdi Vasheghani Farahani; Kiavash Hushmandi; Milad Ashrafizadeh; Haroon Khan; Alan Prem Kumar
Journal:  Antioxidants (Basel)       Date:  2021-02-26

Review 8.  MRTF: Basic Biology and Role in Kidney Disease.

Authors:  Maria Zena Miranda; Zsuzsanna Lichner; Katalin Szászi; András Kapus
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.